What’s Next for Aerpio Pharmaceuticals Inc (NASDAQ:ARPO) After Having Less Shares Shorted?

September 16, 2018 - By Brian Ramirez

The stock of Aerpio Pharmaceuticals Inc (NASDAQ:ARPO) registered a decrease of 2.08% in short interest. ARPO’s total short interest was 4,700 shares in September as published by FINRA. Its down 2.08% from 4,800 shares, reported previously. With 39,100 shares average volume, it will take short sellers 0 days to cover their ARPO’s short positions. The short interest to Aerpio Pharmaceuticals Inc’s float is 0.02%.

The stock decreased 1.94% or $0.07 during the last trading session, reaching $3.54. About 85,215 shares traded. Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) has 0.00% since September 16, 2017 and is . It has underperformed by 15.62% the S&P500.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company has market cap of $143.47 million. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It currently has negative earnings. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease.

Another recent and important Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO) news was published by Businesswire.com which published an article titled: “Annual Rodman & Renshaw Global Investment Conference, sponsored by HC Wainwright & Co., LLC” on August 24, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.